About us

 
NeuClone has developed technology for the safe and economic manufacturing of biological drugs. The NeuMAX™ platform is used to generate robust industrial cell lines with enhanced therapeutic protein expression to manufacture biological Active Pharmaceutical Ingredients (APIs). NeuClone licenses regulatory-approved cell lines engineered to produce a range of protein therapeutics and provides ongoing support and in-house training to licensees, ensuring successful pipeline integration.  At its facility in Sydney, NeuClone provides its clients with the tools, skills and capabilities to manufacture biological APIs using its proprietary cell lines and processes.

 

Newsroom:

 

CNBC interview with Lupin CFO discussing recent licensing agreement with NeuClone

 

Download our One Pager / Fact Sheet

 

 

Mission Statement

NeuClone is dedicated to integrity in the development of cell lines for the ethical and safe production of biological drugs to cure, prolong and improve the life of patients.

 

Biosimilars

NeuClone's world-class scientists bring their expertise to the biosimilars stage to help our clients succeed in ther biosimilars projects.

Read more.

Our Technology

NeuMAX™ is a robust, high-yielding production platform for manufacturing protein therapeutics in CHO cells.

Read more.

Careers

NeuClone is seeking skilled scientists with expertise in cell line development

Read more